Date: 2013-06-06
Type of information: Production agreement
Compound: cGMP biopharmaceuticals facility
Company: Boehringer Ingelheim (Germany) Zhangjiang Biotech & Pharmaceutical Base Development Company (China)
Therapeutic area:
Type agreement: collaboration
manufacturing
production
Action mechanism:
Disease:
Details: * On June 6, 2013, Boehringer Ingelheim has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company in Pudong, Shanghai a strategic alliance agreement and contract to build a cGMP biopharmaceuticals facility. The new site will provide full range of development and clinical services to Chinese and multi-national customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China utilizing mammalian cell culture technology. The facility set up will include technical process development and cGMP manufacturing which will be ready for operations early 2016. Boehringer Ingelheim plans an investment of over €35 million. The project will create up to 65 job opportunities with high qualification standards.
Financial terms:
Latest news:
